Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;70(3):839-845.
doi: 10.4103/ijo.IJO_1791_21.

Pars plana Aurolab aqueous drainage implantation for refractory glaucoma: Outcome of a new modified technique

Mohideen A Kader  1 , Shylesh B Dabke  1 , Aakriti G Shukla  2 , Venugopal Reddy  3 , Syed M Abdul Khadar  3 , Devendra Maheshwari  1 , Rengappa Ramakrishnan  1
Affiliations

Pars plana Aurolab aqueous drainage implantation for refractory glaucoma: Outcome of a new modified technique

Mohideen A Kader et al. Indian J Ophthalmol. 2022 Mar.

Abstract

Purpose: To report the outcomes of pars plana insertion of Aurolab aqueous drainage implant (AADI) in adults with refractory glaucoma by the novel technique of making scleral tunnel instead of patch graft to cover the tube to prevent its migration.

Methods: A retrospective study was done between April 2016 and April 2018 on patients with ≥12 months of follow-up. The main outcome measure was a surgical failure at 12 months. The failure was defined as intraocular pressure (IOP) >18 mmHg or IOP ≤5 mmHg on two consecutive follow-up visits after 3 months, reoperation for glaucoma, loss of light perception vision, or implant explantation. Alternate definitions of failure including IOP >21 and IOP >15 mmHg were also considered.

Results: : The study included 32 eyes of 32 patients. The mean age was 46.2 ± 17.5 years. The most common etiology is traumatic glaucoma (12 eyes, 37.5%). The mean preoperative IOP and anti-glaucoma medications were 43.3 ± 10.3 and 3.4 ± 0.5 mmHg, respectively; both the parameters at the final follow-up were reduced to 15.2 ± 8.1 and 1.6 ± 0.5 mmHg. The Kaplan-Meier survival estimates demonstrated that the cumulative probability of failure was 15.6% (95% CI; 6.8-33.5%) at 3 months, 18.7% (95% CI; 8.9-37.0%) at 6 months, and 25.0% (95% CI; 13.4-43.8%) at 12 months.

Conclusion: Pars plana AADI implantation with a newer modification technique is a useful procedure in reducing IOP and the number of anti-glaucoma medications in the eyes with refractory glaucoma. The visual acuity may be stabilized with the concurrent treatment of posterior segment pathology.

Keywords: Ahmed glaucoma valve; Aurolab aqueous drainage implant; Baerveldt glaucoma implant; glaucoma surgery; tube shunt.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Kaplan–Meier curve demonstrating cumulative failure rate with 95% confidence interval through postoperative month 12.
Figure 2
Figure 2
Distribution of intraocular pressure through postoperative month 12.
See this image and copyright information in PMC

Comment in

References

    1. Joshi AB, Parrish RK, Feuer WF. 2002 survey of the American Glaucoma Society:Practice preferences for glaucoma surgery and antifibrotic use. J Glaucoma. 2005;14:172–4. - PubMed
    1. Hyung SM, Kim SK. Mid-term effects of trabeculectomy with mitomycin C in neovascular glaucoma patients. Korean J Ophthalmol. 2001;15:98–106. - PubMed
    1. Chow K, Mora J. Practice preferences for glaucoma drainage device implantation and cyclodestruction in Australia and New Zealand. J Glaucoma. 2012;21:199–205. - PubMed
    1. Knape RM, Szymarek TN, Tuli SS, Driebe WT, Sherwood MB, Smith MF. Five-year outcomes of eyes with glaucoma drainage device and penetrating keratoplasty. J Glaucoma. 2012;21:608–14. - PMC - PubMed
    1. Ceballos EM, Parrish RK, Schiffman JC. Outcome of Baerveldt glaucoma drainage implants for the treatment of uveitic glaucoma. Ophthalmology. 2002;109:2256–60. - PubMed